Multiple sclerosis research
Studies of Cortexin, Cerebrolysin, Phenotropil and Xemys, case reports from a Bemitil patent, and the history of metabolic approaches to MS.
Findings from selected studies
- Motor scores in 63 adults with MS
After three courses, upper-limb scores improved by 1.4 points with adjunctive Cortexin versus 0.8 with standard care alone. Lower-limb gains were 1.8 versus 0.9 points. The study did not establish an effect on relapses or disability progression.
Findings in people with MS
The 2009 Cortexin study reported no statistically significant change in EDSS disability scores. The 2025 comparison reported gains in limb motor scores with adjunct Cortexin. The Bemitil patent describes one patient in detail who received several treatments at the same time.
The Xemys clinical and biomarker reports follow the same Phase I cohort. Disability measures were unchanged at the end of the study, and MRI activity increased temporarily. The evidence leaves effects on remyelination, relapses and long-term disability unresolved.
The Cerebrolysin comparison found no between-group difference in EDSS disability scores. The Phenotropil report assessed fatigue, mood and quality of life during adjunctive care. Most participants also received disease-modifying therapy.
[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression].
Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed · Journal publication
Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
No between-group EDSS difference was reported; selected functional and neurophysiological measures differed.
Results and tables
Reported findings and study design
40 patients recovering from an MS relapse: 20 Cerebrolysin versus 20 saline after methylprednisolone 1,000 mg/day for five days. Cerebrolysin 20 mL/day for ten administrations; follow-up 3–4 weeks.
Population or model 40 patients during regression of a multiple-sclerosis relapse after steroid treatment
Dose, route and schedule
After methylprednisolone 1,000 mg/day for five days, the study used Cerebrolysin 20 mL in 200 mL saline once daily for ten administrations, compared with saline. This was sequential adjunctive treatment during recovery from an MS relapse.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Completed treatment | 17/20 (85%) versus 18/20 (90%) | |
| Baseline age | 27.35 (5.65) versus 26.65 (4.93) years | |
| Baseline disease duration | 29.9 (11.01) versus 30.25 (11.98) months | |
| Baseline EDSS | 3.5 [2.0;4.5] versus 3.0 [1.5;4.5] | |
| Follow-up EDSS | 2.0 [1.75;2.5] versus 2.5 [1.75;2.5] | No significant between-group difference · p=0.665 |
| MSFC and SDMT | Greater improvement in the treated group | p=0.038 and p=0.026 |
| Visual test comparison | No significant difference | p=0.658 |
| Neurophysiological abnormality regression | 70.59% versus 27.78% | p=0.028 |
| Neurophysiological deterioration | 10% versus 30% | p=0.228 |
| Gadolinium-positive MRI lesions | 14 before versus 12 afterward | Four treated patients only |
Small short-term comparison. MRI lesion counts from four treated patients cannot establish remyelination or disease modification.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 40 patients during regression of a multiple-sclerosis relapse after steroid treatment
- Source reviewed
- Citation and indexed abstract checked. Full methods, funding and risk of bias have not been comprehensively appraised.
Study limitations
- Short follow-up, attrition and a very small MRI subset limit interpretation. Surrogate changes do not establish remyelination.
Reviewed 2026-09-30.
Experience using Phenotropil in combined treatment of multiple sclerosis
D. V. Sazonov, O. V. Ryabukhina, E. V. Bulatova, N. A. Malkova, A. V. Babenko · Atmosfera. Nervnye bolezni. No. 4, 2010, as labeled by host
The report examines asthenia, mood and quality-of-life measures during adjunctive treatment. Most participants also received disease-modifying therapy.
- Population / setting
- 39 patients with relapsing or secondary-progressive multiple sclerosis
- Source reviewed
- Original study text in a medical-portal reprint checked; publication edition not independently matched.
Study limitations
- Uncontrolled adjunctive design; treatment contributions cannot be separated.
- The host labels the reprint as Atmosfera, No. 4, 2010; earlier reprints circulate and edition matching remains open.
Reviewed 2026-09-29.
Effect of Cortexin on neuroplasticity in multiple sclerosis
Format: Publisher article and Russian PDF · Reviewed: Publisher full-text results narrative and available tables checked on 1 November 2026
S. V. Kotov, T. I. Yakushina, V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. 2009;(3):14–16
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
Results and tables
Reported findings and study design
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
20 adults with relapsing-remitting MS in stable remission; two ten-day courses of 10 mg intramuscular Cortexin with a two-week interval; no control group.
Population or model 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Beck depression score | 17.6 ± 1.3 → 12.9 ± 1.4 points | Within-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline |
| EQ-5D health score | 0.41 ± 0.07 → 0.73 ± 0.03 | Within-person change; higher score indicates better reported health · After treatment · p<0.05 versus baseline |
| EDSS disability | No significant change | Participants entered in remission with EDSS below 3 |
| Adverse events | None observed in 20 participants | Small, short open study; not a long-term safety estimate |
These results concern symptoms and quality of life in an uncontrolled cohort. Stable EDSS during a short remission-period study does not demonstrate remyelination or prevention of disease progression.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
- Source reviewed
- Publisher full-text results narrative and available tables checked on 1 November 2026
Study limitations
- Open prospective study without a control group, randomization or blinding.
- Participants were already in remission; stable EDSS does not demonstrate prevention of progression.
- No adverse events were observed in this small sample; safety and disease modification are not established.
Reviewed 2026-11-01.
Neuropeptide immunocorrection in patients with multiple sclerosis
Cortexin tissue-derived peptide preparation
Format: Open-access journal PDF; Zenodo repository · Reviewed: Full article read; motor table visually checked
M. A. Artykova, S. A. Beknazarov · Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025
After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.
Results and tables
Reported findings and study design
63 adults with MS aged 18–59: standard care plus Cortexin 33 versus standard care 30; results reported after three courses.
Population or model 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Upper-limb motor-score gain | 1.4 versus 0.8 points | p<0.05 as reported |
| Lower-limb motor-score gain | 1.8 versus 0.9 points | p<0.05 as reported |
| Reduced-work-capacity proportion, add-on arm | 71.7% → 31.1% | |
| Reduced-work-capacity proportion, comparison arm | 75.5% → 53.1% |
Existing full-article extraction; the motor scale and variance are not adequately specified, and percentages lack raw counts. No MRI, relapse or EDSS progression benefit is established.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
- Source reviewed
- Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.
Study limitations
- Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
- Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
- No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
- A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.
Reviewed 2026-10-03.
Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
Format: Patent full text · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
O. V. Dorozhko, G. I. Kovalev, R. M. Salimov · RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006
Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.
Results and tables
Reported patent results
Reported findings
The clinical examples describe improvement during adjunctive Bemitil treatment, without group-level efficacy scores or a controlled patient comparison.
Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
Population or model Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MS illustrative case | Reported clinical/MRI remission, improved strength, coordination, memory, mood and sleep | One 47-year-old patient also receiving piracetam, pentoxifylline and vitamins · After approximately 3 weeks |
| Chronic-fatigue illustrative case | Reported improvement in general condition, tremor, headaches, coordination and perceived weakness | One 29-year-old patient receiving several other medicines · After a 15-day course |
| Animal maze experiment | 216.6 ± 12.1 s with Bemitil versus 304.9 ± 33.3 s after injury alone; uninjured control 224.3 ± 14 s | 25 mice per group; duration to exploration criterion, not a patient disability score |
No aggregate MS relapse, disability-progression or MRI-lesion outcome is supplied for the 10-patient group. Selected adjunctive cases cannot establish disease modification or ME/CFS efficacy.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
- Source reviewed
- The summary reflects the results reported in the cited source.
Study limitations
- Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
- The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
- Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.
Reviewed 2026-11-06.
CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
A. Belogurov Jr., K. Zakharov, Y. Lomakin, K. Surkov, S. Avtushenko, P. Kruglyakov, I. Smirnov, G. Makshakov, C. Lockshin, G. Gregoriadis, D. Genkin, A. Gabibov, E. Evdoshenko · Neurotherapeutics. 2016;13:895–904
EDSS and MRI measures were statistically unchanged at study exit. Active gadolinium-enhancing lesions increased transiently at weeks 7 and 10.
Results and tables
Reported findings and study design
Uncontrolled Phase I study; 20 MS patients enrolled at four Russian centers.
Population or model 20 MS patients enrolled at four Russian centers; open-label Phase I
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| EDSS and MRI at study exit | No statistically significant change versus baseline | |
| Active gadolinium-enhancing lesions | Transient increase at weeks 7 and 10 |
Small open-label study cannot establish clinical efficacy, restored tolerance or long-term safety. Early MRI activity remains relevant despite unchanged exit measures.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- 20 MS patients enrolled at four Russian centers; open-label Phase I
- Source reviewed
- Primary publication checked for Phase I design and clinical/MRI outcomes.
Study limitations
- Uncontrolled safety and proof-of-concept study; not evidence of reduced relapses or disability progression.
- Early MRI activity must be considered alongside the authors’ tolerability findings.
Reviewed 2026-11-05.
Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients
Y. Lomakin, A. Belogurov, I. Glagoleva, A. Stepanov, K. Zakharov, J. Okunola, I. Smirnov, D. Genkin, A. Gabibov · Mediators of Inflammation. 2016:2847232
The paper reports changes in circulating cytokines and chemokines after Xemys exposure.
- Population / setting
- Biomarker analysis from the same Phase I Xemys research program
- Source reviewed
- Original publisher summary checked; linked full text available.
Study limitations
- Same clinical program as the Phase I report; not an independent efficacy trial.
- Biomarker changes do not demonstrate restored immune tolerance or clinical disease modification.
Reviewed 2026-11-05.
Related research in lupus and neuromuscular disease
The Bemitil journal article, patent and dissertation cover lupus and may share participants. Other sources describe hereditary neuromuscular conditions or experiments with cells from healthy donors.
The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus
Format: Indexed English abstract · Reviewed: Abstract reviewed
T. A. Lisitsyna, A. D. Durnev, M. M. Ivanova, A. I. Speranskii, S. B. Seredenin, V. A. Nasonova · Experimental and Clinical Pharmacology. 1999;62(5):38–41. PMID 10572751
The abstract reports reduced anti-DNA antibodies and improvements in SLEDAI-1/ECLAM disease-activity measures in Bemitil-containing treatment groups. Background treatment included prednisolone, with or without cyclophosphamide. Numerical effect sizes are not available in the abstract.
Results and tables
Reported findings and study design
A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.
Four groups of 15, 15, 15 and 16 patients; background prednisolone with different adjuncts; eight-week assessment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Antibodies and lupus activity | Reported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scores | No group-level values or effect sizes in abstract |
| Group sizes | 15, 15, 15 and 16 patients | The count spans multiple groups. |
| Bemitil exposure | 500–750 mg/day orally | Eight-week comparison; the indexed background-drug dose units need original verification |
Several concurrent-treatment arms prevent interpreting this as Bemitil monotherapy. Unverified background-drug units are not reproduced as dosing instructions.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 61 people with SLE; four groups of 15, 15, 15 and 16; eight-week comparison
- Source reviewed
- The summary reflects the results reported in the cited source.
Study limitations
- SLE is a different disease; these findings do not establish efficacy in MS.
- Allocation and blinding cannot be established from the abstract; concomitant therapy complicates attribution.
- The 1997 dissertation and 2000 patent appear to describe the same research program.
Reviewed 2026-10-03.
Method of treating systemic lupus erythematosus
Format: Russian patent with English translation · Reviewed: Original patent and numerical passages checked 5 November 2026
T. A. Lisitsyna and colleagues · RU2157684C2. Filed 22 December 1997; published 20 October 2000
The patent describes four treatment groups using glucocorticoids with or without cyclophosphamide and Bemitil. It reports improvements in selected clinical and laboratory signs and anti-DNA antibodies in the Bemitil groups. This appears to describe the same research program as the 1999 paper.
Results and tables
Reported patent results
Reported findings
The patent reports lower anti-DNA antibodies and steroid changes in adjunctive Bemitil arms of the historical lupus program; unequal groups and follow-up prevent a causal efficacy estimate.
Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.
Population or model 61 SLE patients treated at the Institute of Rheumatology, 1993–1997
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anti-DNA antibodies | Reported within-group reductions in both Bemitil-containing arms | p<0.001 |
| Mean daily prednisolone, group 3 | 23.5 → 18.7 mg/day during observation | |
| Mean daily prednisolone, group 1 | 14.7 → 29.0 mg/day during observation | |
| Reported relapses / exacerbations | 11/30 without Bemitil at 6–12 months; 5/31 with Bemitil at 12–18 months |
Historical treatment observations, not dosing advice. Unequal follow-up, baseline severity and treatment selection preclude a causal steroid-sparing claim or comparative relapse-risk calculation. Patent and paper are not independent replication.
Source for these results ↗ · Reviewed 2026-11-05
- Population / setting
- 61 SLE patients treated at the Institute of Rheumatology, 1993–1997
- Source reviewed
- The summary reflects the results reported in the cited source.
Study limitations
- Patent reproduction; allocation concealment and blinding are not established. Treatment choice also reflected disease severity.
- Numerous outcomes and unequal follow-up periods prevent a simple comparative relapse-rate interpretation.
- Not an MS study or independent confirmation of the 1999 SLE report.
Reviewed 2026-10-03.
Bioenergetic disturbances and their correction in neuromuscular diseases
Format: Russian dissertation abstract, OCR reproduction · Reviewed: Author metadata and relevant text reviewed
L. A. Saikova · Doctoral dissertation author abstract. Saint Petersburg, 1993
The dissertation describes bioenergetic and enzyme-marker changes during treatment, including Bemitil comparisons. It extends the neuromuscular research context of the 1991 and 1992 publications; biochemical changes alone do not establish sustained functional benefit.
- Population / setting
- Neuromuscular disease research program, including hereditary muscular dystrophies
- Source reviewed
- The summary reflects the results reported in the cited source.
Study limitations
- Author is Lyudmila Alekseevna Saikova; attribution to Pustozerov as dissertation author is incorrect.
- OCR reproduction; original scan and cohort overlap with the earlier papers require reconciliation.
- Neuromuscular disorders are not MS; heterogeneous treatments and uncontrolled observations limit inference.
Reviewed 2026-10-03.
Inhibitory effect of 2-substituted benzimidazoles on lymphocyte mitogenesis is associated with AhR-dependent mechanisms
Format: Russian conference abstract; indexed PDF excerpt · Reviewed: Indexed abstract and table text reviewed
E. S. Sibiryak, S. V. Sadovnikov, S. V. Sibiryak · Medical Immunology. 2009;11(4–5):335. Conference abstract
At the reported Bemitil concentration, the table gives only 3±3% inhibition of mitogenesis. The combination with TCDD differed from the Bliss-model expectation. This supports an experimental interaction question, not a claim that Bemitil strongly suppresses human immunity.
- Population / setting
- Healthy-donor T cells stimulated with anti-CD3; benzimidazoles and TCDD interaction experiment
- Source reviewed
- The summary reflects the results reported in the cited source.
Study limitations
- Conference abstract and indexed table excerpt, not a full clinical study.
- AhR involvement is a proposed mechanism; direct receptor binding and clinical immunosuppression were not demonstrated.
- No MS patients, demyelination outcome or clinical benefit assessment.
Reviewed 2026-10-03.
Earlier neuromuscular publications share investigators and may include some of the same participants. 1991 report ↗ · 1992 report ↗
Fatigue and metabolic approaches
The 2015 fatigue study compared Cytoflavin with a multi-drug regimen. The contribution of any individual drug in the comparison regimen remains unclear.
Efficacy of Cytoflavin in patients with multiple sclerosis and fatigue
Format: Publisher full text · Reviewed: Methods and results reviewed
O. A. Mialovitska · Ukrainian Medical Journal. Published 18 March 2015
The Cytoflavin group’s MFIS score fell from 45.1±4.5 to 29±4.2 (reported within-group p<0.05). The comparator regimen included pentoxifylline, piracetam, meldonium and B vitamins. The result cannot be attributed to either piracetam or meldonium.
- Population / setting
- 62 screened; 53 with fatigue allocated to Cytoflavin (20) or conventional therapy (33)
- Source reviewed
- The summary reflects the results reported in the cited source.
Study limitations
- Unequal groups; randomization and blinding are not established.
- 62 is the screened population, not the number allocated to treatment groups.
- A within-group change is not a demonstrated between-group effect; fatigue improvement is not disease modification.
Reviewed 2026-10-03.
Bibliography and original sources
Cortexin neuroplasticity in MS — original PDF
S. V. Kotov; T. I. Yakushina; V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. (3):14–16
This publisher PDF contains the same 2009 Cortexin study summarized above.
Source record ↗Cyclophosphamide and Bemitil: antioxidant status and DNA integrity in SLE and rheumatoid arthritis
T. A. Lisitsyna · Dissertation author abstract; reported 23 pages
The catalogue identifies the author abstract. Participant overlap with the 1999 lupus article and 2000 patent remains uncertain.
Source record ↗Neuromuscular rehabilitation — publisher title/abstract mismatch
V. S. Lobzin; L. A. Saikova; V. D. Kosachev; V. G. Pustozerov; T. N. Vasilyeva · Neurology Bulletin. XXVI(1–2):51–54. DOI 10.17816/nb107044
English title describes traumatic/compressive neuropathies, but abstract concerns hereditary neuromuscular disorders. The abstract attributes more than 1,000 observations to the broader rehabilitation program. The size of the Bemitil group remains unclear.
Source record ↗Multiple sclerosis: metabolic disturbances and pathogenetic treatment — dissertation citation trail
Yu. N. Savchenko · Doctoral author abstract, Moscow, 36 pages; cited in later patent
A later patent cites a 36-page author abstract. Other references give 1994 and 369 pages. The original methods and results for glycine remain unavailable.
Source record ↗Myelinopathies and demyelinating diseases
A. P. Khokhlov; Yu. N. Savchenko · Moscow: Meditsina. 207,[1] pages. ISBN 5-225-00726-0
The university catalogue confirms the book. The available entry supplies bibliographic information.
Source record ↗Myelin metabolism paper — bibliographic reference
Associated with A. P. Khokhlov and Yu. N. Savchenko · Zhurnal Nevropatologii i Psikhiatrii. 90(8); pages reported as 104–109, conflicting citation 104–113
Secondary bibliographies give different page ranges. The original article would clarify its title, methods and findings.
Source record ↗Membrane-destabilizing processes in erythrocytes of patients with multiple sclerosis
A. A. Sokolova · Candidate medical dissertation, Kazan
Dissertation reproduction describes membrane and oxidative-stress research. Biomarker associations do not establish efficacy of Bemitil or another treatment.
Source record ↗Historical Russian methodological recommendations No. 2000/166
Russian Ministry of Health · 17 November 2000; reproduced document
This historical guidance lists piracetam and Cerebrolysin among adjunct treatments.
Source record ↗Historical multiple-sclerosis management protocol
Russian clinical protocol · 18 April 2005
Nootropic adjuncts, including piracetam and Cerebrolysin, appear with grade-C evidence. This historical recommendation does not establish modern clinical efficacy.
Source record ↗Marketing research on medicine provision for people with MS in Tyumen
O. V. Kolenchik · Dissertation, 114 pages
The catalogue and excerpts describe prescribing patterns in Tyumen. The full dissertation is needed to verify utilization figures.
Source record ↗Prospects of metabolic therapy in multiple sclerosis
G. N. Bisaga · Third RUCTRIMS congress abstract
The congress abstract discusses metabolic approaches and acknowledges the limited clinical evidence.
Source record ↗Study of DNA damage of blood mononuclear cells in SLE by DNA-comets
See indexed author list · PMID 9532374
The indexed record concerns DNA damage in lupus. Bemitil exposure is unconfirmed.
Source record ↗Open questions in the evidence
- Whether the 2021 and 2025 Cortexin reports share participants.
- Outcomes for the other nine MS cases mentioned in the Bemitil patent.
- Whether cohorts described as encephalomyelopolyradiculoneuritis meet current MS diagnostic criteria.
- Effects on disability, relapses and safety in larger controlled studies.
Stroke research ↗ · Autoimmune research ↗ · Complete bibliography ↗ · Research map ↗